BioSpace News Archive

Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that RAFA is in active meetings the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center at the university.

Defence has optimized the chemical manufacturing of its experimental antigens to efficiently link the Accum moiety.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 10:15 A.M. Eastern Time.

Microba Life Sciences, leaders in precision gut microbiome science, have demonstrated the superiority of their faecal sample preservation method against others, with a robust, peer-reviewed study published in ISME Communications.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that, in response to the continued public health concerns regarding in-person gatherings as a result of the ongoing COVID-19 pandemic and to continue to support the health and well-being of its stockholders, directors, and employees, the Company’s annual meeting

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the following upcoming investor conferences

– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised approximately $30 million, before offering expenses, in an underwritten public offering – – Granted Torii Pharmaceutical Co., Ltd. an exclusive license to develop and commercialize VP-102 for molluscum and common warts in Japan; Company recognized license revenues of $12.0 million in the first quarter –

KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year